GC
TXMD icon

GMT Capital’s TherapeuticsMD TXMD Stock Holding History

GMT Capital’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-119,721
Closed -$7.24M – 59
2020
Q4 		$7.24M Hold
119,721
– – 0.52% 26
2020
Q3 		$9.46M Hold
119,721
– – 0.69% 31
2020
Q2 		$7.48M Buy
119,721
+16,905
+16% +$984K 0.42% 38
2020
Q1 		$5.45M Buy
+102,816
New +$10.2M 0.31% 48

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GMT Capital's TXMD Position: Q1 2021 in Review

GMT Capital sold out of TherapeuticsMD (TXMD) in Q1 2021, closing a stake of 119,721 shares — an estimated $7.24M sold.

GMT Capital first reported a position in TXMD in Q1 2020 and held it in 4 quarters. The position peaked at $9.46M in Q3 2020. 160 funds tracked by Wall St. Rank hold TXMD as of Q1 2021.

  • GMT Capital reported no remaining TherapeuticsMD position as of Q1 2021 after selling out during the quarter.
  • GMT Capital sold 119,721 TherapeuticsMD shares in Q1 2021, an estimated $7.24M.
  • GMT Capital first reported a position in TherapeuticsMD in Q1 2020 and held it in 4 quarters.
  • GMT Capital's TherapeuticsMD position peaked at $9.46M in Q3 2020.
  • 160 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2021.

Based on GMT Capital's 13F filing for Q1 2021, filed 13 May 2021.